Natural Killer Cell Immunotherapy for Cancer
Our Novel Approach
Our Technology
-
KIR2DS2 is a novel, patented activating NK cell receptor associated with better cancer outcomes
-
We are developing a vaccine-like RNA therapeutic, KG001, that activates KIR2DS2 and leads to significant expansion of the KIR2DS2+ population
-
We have further identified cancer specific ligands for KIR2DS2 forming the basis for a stratified medicine approach to treatment
-
We have demonstrated efficacy in mouse models including HCC, our fist target indication
-
By contrast with other approaches, KG001 leads to long-lived NK cells, is cheap and easy to administer
-
KG001 has significant potential for use with adjuvants and in combination, e.g. with, anti-PD1, anti-CD20, CAR-T
-
We have a pipeline through the identification of further activating KIR and characterisation of their activating ligands
Pipeline
About Kargenera
Kargenera was founded to commercialise technology developed at the University of Southampton. The technology platform has benefited from over £2m of grant funding from bodies such as MRC, CRUK and the British Liver Trust..
​
The company has assembled a team of experienced academics, lifescience executives and scientific advisors, led by the founder, Prof Salim Khakoo.
Prof. Salim Khakoo, Founder and CSO
Professor of Hepatology & Director of Biomedical Research at the University of Southampton. With a twenty year track record of academic research into NK cell biology, Salim is a true expert in the field.
Dr Jim Millen, Executive Chairman
Over 15 years’ experience in pharmaceuticals and biotechnology business/ corporate development across big pharma and biotech. Currently Chairman of oncology consultancy Physiomics and non-executive director several biotech ventures.
Nick Cetateanu, Senior Advisor
A Pharma/Biotech executive with a scientific background, Nick has held a number of positions in his 20-year career, across Strategy, Operations, Marketing, Clinical Development, BD&L and Consulting.
Research
Our technology has attracted significant ongoing research grants from the Medical Research Council (MRC) and Cancer Research UK (CRUK)
Our technology has been published in high impact journals
Science Immunology
Immune Response Genetics
Journal for Immunotherapy in Cancer
Journal of Immunology
